Breast Cancer Relapse, Chemotherapy Effectiveness Can Now Be Determined By Gene

Novel Gene for breast cancerA recent study entitled “DEAD-box helicase DP103 defines metastatic potential of human breast cancers and published in the Journal of Clinical Investigation, identified a gene that can help to predict both breast cancer relapses and responses to chemotherapy, allowing doctors to customize treatment regimens personalized to each individual patient depending on their breast cancer classification. Even though breast cancer treatments have been the focus of intense research, 30% of patients with early breast cancers will suffer from relapse with distant metastasis, and some of them do not respond to chemotherapy. So far, it has been a challenge to identify patients at risk for relapse. As a result, the need to identify markers and therapeutic targets for metastatic breast cancers led a group of scientists from A*STAR’s Institute of Molecular and Cell Biology (IMCB), and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to team up in an attempt to fill this gap. Their results revealed that DEAD-box helicase DP103 is a biomarker a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.